Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

ReTUNE study shows remission of type 2 diabetes possible in non-obese people

Close up of Stethoscope with Glucose meter for check blood sugar level, lancet, tape measure and green vegetable fresh tomato, cucumber coriander and spring onion.

The Reversal of Type 2 diabetes Upon Normalisation of Energy intake in the non-obese (ReTUNE) study, funded by Diabetes UK, was designed to test the Personal Fat Threshold hypothesis first proposed by Professors Roy Taylor (Newcastle University) and Rury Holman (Clin Sci [Lond]. 2015;128:405-410).

ReTUNE postulated that the mechanistic changes underpinning weight loss-induced remission of type 2 diabetes in people with a body mass index <27kg/m2 would be the same as those observed previously in people with a body mass index >27kg/m2.

The primary results of the ReTUNE study (Clin Sci [Lond]. 2023;137:1333-1346) confirm for the first time that non-obese people with type 2 diabetes can be supported to put their type 2 diabetes into remission through a structured low-calorie diet, and that the key to this is losing harmful fat from the liver and pancreas. Professors Taylor and Holman concluded that type 2 diabetes occurs if a person exceeds their personal fat threshold and becomes too heavy for their own constitution, irrespective of their body mass index.

Access the recently published paper here.

Similar stories

Under-40s diagnosed with type 2 diabetes have a mortality rate four times higher than the general population

People diagnosed with type 2 diabetes before 40 years of age, have nearly four times the risk of death compared with the general UK population, a new study carried out at the University of Oxford’s Radcliffe Department of Medicine has found.

Hydroxychloroquine provides moderate COVID-19 prevention

COPCOV, the world’s largest COVID-19 chemoprevention study, published results today showing that hydroxychloroquine (HCQ) has a moderate benefit in preventing COVID-19. The COPCOV trial was led globally by the Mahidol Oxford Tropical Medicine Research Unit (MORU), Thailand. The Diabetes Trials Unit (DTU) was the UK coordinating centre for the trial, helped develop the protocol, and was responsible for managing UK sites, approvals and procedures.

Patients receiving steroids are more than twice as likely to develop diabetes, UK study has found

Patients who are being treated with systemic glucocorticoids are more than twice as likely to develop diabetes as those not receiving the treatment, a new study by researchers at the Radcliffe Department of Medicine’s Diabetes Trial Unit has found.

Early blood glucose control for people with type 2 diabetes is crucial for reducing complications and prolonging life

Research led by scientists from the Universities of Oxford and Edinburgh has found that early good blood glucose control can minimise the lifetime risk of diabetes-related complications, including heart attacks, kidney failure and vision loss.

The LEGEND-D Trial – which aims to prevent low blood sugar levels in type 1 diabetes – is open to recruitment

The first participant has completed initial study activities and is now randomised to one of the trial’s arms.

DTU to run clinical trial for Dementias Platform UK in nationwide bid to revolutionise dementia diagnosis using blood tests

Dementias Platform UK has been awarded over £4 million to carry out countrywide trials to identify accurate and quick blood tests that can diagnose dementia, in a bid to improve management and patient and carer wellbeing. RDM's Diabetes Trials Unit will run the clinical trial component of the challenge.

Similar stories

Under-40s diagnosed with type 2 diabetes have a mortality rate four times higher than the general population

People diagnosed with type 2 diabetes before 40 years of age, have nearly four times the risk of death compared with the general UK population, a new study carried out at the University of Oxford’s Radcliffe Department of Medicine has found.

Hydroxychloroquine provides moderate COVID-19 prevention

COPCOV, the world’s largest COVID-19 chemoprevention study, published results today showing that hydroxychloroquine (HCQ) has a moderate benefit in preventing COVID-19. The COPCOV trial was led globally by the Mahidol Oxford Tropical Medicine Research Unit (MORU), Thailand. The Diabetes Trials Unit (DTU) was the UK coordinating centre for the trial, helped develop the protocol, and was responsible for managing UK sites, approvals and procedures.

Patients receiving steroids are more than twice as likely to develop diabetes, UK study has found

Patients who are being treated with systemic glucocorticoids are more than twice as likely to develop diabetes as those not receiving the treatment, a new study by researchers at the Radcliffe Department of Medicine’s Diabetes Trial Unit has found.

Early blood glucose control for people with type 2 diabetes is crucial for reducing complications and prolonging life

Research led by scientists from the Universities of Oxford and Edinburgh has found that early good blood glucose control can minimise the lifetime risk of diabetes-related complications, including heart attacks, kidney failure and vision loss.

The LEGEND-D Trial – which aims to prevent low blood sugar levels in type 1 diabetes – is open to recruitment

The first participant has completed initial study activities and is now randomised to one of the trial’s arms.

DTU to run clinical trial for Dementias Platform UK in nationwide bid to revolutionise dementia diagnosis using blood tests

Dementias Platform UK has been awarded over £4 million to carry out countrywide trials to identify accurate and quick blood tests that can diagnose dementia, in a bid to improve management and patient and carer wellbeing. RDM's Diabetes Trials Unit will run the clinical trial component of the challenge.